Weight regain after successful obesity treatment remains one of medicine's most stubborn challenges, with most people eventually returning to their baseline weight within years. This reality makes maintenance strategies as critical as initial weight loss interventions for achieving lasting health benefits.
The SURMOUNT-MAINTAIN trial tracked 1,289 adults who first achieved substantial weight loss during a 60-week open-label period using tirzepatide at maximum tolerated doses (10-15 mg weekly). Participants were then randomized to continue their maximum dose, reduce to 5 mg weekly, or switch to placebo for 52 additional weeks. Those maintaining their maximum dose sustained weight loss significantly better than the placebo group, while the reduced-dose arm showed intermediate results. The study incorporated a rescue protocol allowing participants to restart tirzepatide if weight regain exceeded 50% of their initial loss.
This maintenance approach represents a paradigm shift from traditional obesity treatment models that focus primarily on initial weight loss. The findings align with emerging evidence that obesity involves persistent metabolic adaptations requiring ongoing pharmaceutical intervention rather than short-term treatment courses. However, the study's design limits real-world applicability since participants had already demonstrated tolerance to higher doses during the lead-in period. The 112-week duration, while substantial, remains relatively short for assessing true long-term maintenance patterns. For adults considering tirzepatide, these results suggest that sustained treatment may be necessary to preserve weight loss benefits, similar to management approaches for other chronic metabolic conditions like diabetes or hypertension.